β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Robert Vassar(Amgen (United States)), Brian D. Bennett(Amgen (United States)), Safura Babu‐Khan(Amgen (United States)), Steve Kahn(Amgen (United States)), Elizabeth A. Mendiaz(Amgen (United States)), Paul Denis(Amgen (United States)), David B. Teplow(Brigham and Women's Hospital), Sandra L. Ross(Amgen (United States)), Patricia Amarante(Amgen (United States)), Richard Loeloff(Amgen (United States)), Yi Luo(Amgen (United States)), Seth Fisher(Amgen (United States)), Janis Fuller(Amgen (United States)), Steven Edenson(Amgen (United States)), Jackson Lile(Amgen (United States)), Mark A. Jarosinski(Amgen (United States)), Anja Leona Biere(Amgen (United States)), Eileen Curran(Amgen (United States)), Teresa L. Burgess(Amgen (United States)), Jean-Claude Louis(Amgen (United States)), Frank M. Collins(Amgen (United States)), James Treanor(Amgen (United States)), Gary N. Rogers(Amgen (United States)), Martin Citron(Amgen (United States))
Science
October 22, 1999
Cited by 3,820Open Access
Full Text

Abstract

Cerebral deposition of amyloid beta peptide (Abeta) is an early and critical feature of Alzheimer's disease. Abeta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.


Related Papers